Cytotoxic activity of quinolinequinones in cancer: In vitro studies, molecular docking, and ADME / PK profiling
Chemical Biology & Drug Design · 2023
DOI: 10.1111/cbdd.14314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2023. Verfasst von Ayse Tarbin Jannuzzi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Pharmaceutical Toxicology, İstanbul University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
Lead molecules containing 1,4‐quinone moiety are intriguing novel compounds that can be utilized to treat cancer owing to their antiproliferative activities. Nine previously reported quinolinequinones ( AQQ1‐9 ) were studied to better understand their inhibitory profile to produce potent and possibly safe lead molecules. The National Cancer Institute (NCI) of Bethesda chose all quinolinequinones ( AQQ1‐9 ) based on the NCI Developmental Therapeutics Program and tested them against a panel of 60 cancer cell lines. At a single dose and five further doses, AQQ7 significantly inhibited the proliferation of all leukemia cell lines and some breast cancer cell lines. We investigated the in vitro cytotoxic activities of the most promising compounds, AQQ2 and AQQ7 , in MCF7 and T‐47D breast cancer cells, DU‐145 prostate cancer cells, HCT‐116 and COLO 205 colon cancer cell lines, and HaCaT human keratinocytes using the MTT assay. AQQ7 showed particularly high cytotoxicity against MCF7 cells. Further analysis showed that AQQ7 exhibits anticancer activity through the induction of apoptosis without causing cell cycle arrest or oxidative stress. Molecular docking simulations for AQQ2 and AQQ7 were conducted against the COX, PTEN, and EGFR proteins, which are commonly overexpressed in breast, cervical, and prostate cancers. The in vitro ADME and in vivo PK profiling of these compounds have also been reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Department of Pharmaceutical Toxicology, İstanbul University, Istanbul, Turkey.
- Department of Biochemistry, School of Medicine/Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, Istanbul, Turkey.
- Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India.
- Bioanalysis, Eurofins Advinus BioPharma Services India Pvt Ltd., Bengaluru, Karnataka, India.
- Adgyl Lifesciences Private Limited, Bengaluru, Karnataka, India.
- Department of Chemistry, Engineering Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Zitieren
APA
Jannuzzi, A. T., Yilmaz Goler, A. M., Shilkar, D., Mondal, S., Basavanakatti, V. N., Yıldırım, H., Yıldız, M., Çelik Onar, H., Bayrak, N., Jayaprakash, V., & TuYuN, A. F. (2023). Cytotoxic activity of quinolinequinones in cancer: In vitro studies, molecular docking, and ADME / PK profiling. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14314
Vancouver
Jannuzzi AT, Yilmaz Goler AM, Shilkar D, Mondal S, Basavanakatti VN, Yıldırım H, et al. Cytotoxic activity of quinolinequinones in cancer: In vitro studies, molecular docking, and ADME / PK profiling. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14314
BibTeX
@article{Jannuzzi2023,
author = {Jannuzzi, Ayse Tarbin and Yilmaz Goler, Ayse Mine and Shilkar, Deepak and Mondal, Subodh and Basavanakatti, Vinay N and Yıldırım, Hatice and Yıldız, Mahmut and Çelik Onar, Hülya and Bayrak, Nilüfer and Jayaprakash, Venkatesan and TuYuN, Amaç Fatih},
title = {Cytotoxic activity of quinolinequinones in cancer: In vitro studies, molecular docking, and ADME / PK profiling},
journal = {Chemical Biology & Drug Design},
year = {2023},
doi = {10.1111/cbdd.14314}
}
EUVIMED